2.10
+0.02(+0.96%)
Currency In USD
Address
44370 Old Warm Springs Boulevard
Fremont, CA 94538
United States of America
Phone
510 668 0881
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
November 10, 2004
| Name | Title | Pay | Year Born |
| Uttam Yashwant Patil | Chief Executive Officer & Interim Chief Financial Officer | 0 | 1986 |
| Tsung-Shann Jiang | Chief Scientific Officer, Chief Strategy Officer & Director | 200,000 | 1953 |
| Eugene Jiang | Chairman & Chief Business Officer | 200,000 | 1986 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.